5.1.1. New Agents. New agents have recently emerged for the treatment of patients nonrespondent to PPI treatment. address this clinical issue, research efforts have focused on inhibition that is, inhibition of transient lower esophageal relaxations Rs), the predominant mecha anism of GERD. Thus the y-aminobutyric acid (GABA) type B (GABAB) receptor has emerged as one of the most